Below are highlights of several recent successes and new directions.

Gleevec®: A Revolutionary Drug for CML Patients

Since its approval by the Food and Drug Administration (FDA) in 2001, Gleevec® has become the standard first-line therapy for newly diagnosed chronic myeloid leukemia (CML) patients. LLS helped advance this groundbreaking targeted therapy and supported the researchers who helped develop the more recently approved drugs, Sprycel® and Tasigna®.  These drugs make it possible for patients to survive many years with good quality of life. The 10-year survival rate has been remarkably improved, from approximately one in ten to nearly nine in ten for chronic phase CML patients (including children). Gleevec® is also approved for patients with rare skin and stomach tumors, and showing promise in many other cancers.

Velcade®: Improved Outcomes for Myeloma Patients

Before Velcade® was approved in 2008 as a first-line therapy for myeloma, patients' median survival rate was less than three years. Today, thanks to Velcade® and other new targeted drugs, people with myeloma have a median survival rate that's three times longer, and they are living with better quality of life since the drugs are less toxic than previous treatments. Velcade® is also approved for people with mantle cell lymphoma, and is being tested as a treatment for other cancers including other lymphomas and leukemias.

Rituxan®: A Targeted Therapy for Lymphoma Patients

Rituxan®, a monoclonal antibody drug, was FDA approved for follicular non-Hodgkin lymphoma (NHL) patients in 1997. In fact, it was the very first targeted drug approved in the U.S. LLS-funded researchers found that Rituxan® can dramatically improve chemotherapy effectiveness, and the FDA approved Rituxan® to be used in combination with other chemotherapy drugs for people with follicular lymphoma and other non-Hodgkin lymphoma types. It's contributed to a doubling of the survival rate for NHL patients, and is now also FDA approved as a treatment for patients with chronic lymphocytic leukemia or Hodgkin lymphoma.

Immunotherapies: Building a Stronger Immune System

Many people with blood cancers suffer from weakened immune systems caused by immune (white blood) cells becoming cancerous and overwhelming normal immune cells, and/or by the powerful treatments that cancer patients receive. Our researchers are working to (1) target the malignant immune cells while leaving healthy cells untouched and (2) strengthen patients' healthy immune cells through the use of vaccines, antibodies or growth factors. Immunotherapies can reduce patients' risks for life-threatening infections and effectively fight the cancers too.

Making Today's Therapies Safer

Beyond debilitating a patient's immune system, standard cancer treatments can cause other serious long-term and late effects. While supporting the development of entirely new targeted therapies and immunotherapies, LLS is also funding researchers who are working to learn how to predict, manage and even prevent these effects that reduce a patient's quality of life or even threaten their life.
For example, aggressive therapies for acute lymphoblastic leukemia (ALL) save many children with this cancer, but can cause significant medical complications. While some LLS-funded experts are developing new, less toxic treatments for pediatric ALL, other LLS investigators are discovering genetic risk factors that can help predict problems before they happen and treatments that reduce the severity of late treatment effects when they occur.